![LYEL logo]()
Lyell Immunopharma :
LYEL
LYEL
Stock Data
$11.97
$1.08 (8.28%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Lyell Immunopharma Inc is a pioneering force in the field of cell therapy, focusing on the development of innovative treatments for patients with solid tumors. By leveraging cutting-edge genetic and epigenetic reprogramming technologies, the company aims to create more effective and durable T cell therapies. Its product pipeline includes LYL797 and LYL845, both in Phase 1 clinical trials, and LYL119 in preclinical development, targeting a range of solid tumors with enhanced potency. Based in South San Francisco, California, Lyell Immunopharma also collaborates with notable institutions and companies to advance its research and potential therapies.
